NICE Single Technology Appraisal Guidance No 173 – Tenofovir
disoproxil for the treatment of chronic hepatitis B
NICE Single Technology Appraisal Guidance No 173 –
Tenofovir disoproxil for the treatment of chronic hepatitis
B
The web reference for the appraisal and other related documents
is: www.nice.org.uk/TA173
NHSScotland should note
that:
1. Recommendations of NICE Single Technology Appraisals (STAs) have
no status in NHS Scotland.
2. NHS Boards should continue to adhere to the SMC advice.
3. The Scottish Medicines Consortium (SMC) published a Statement
of Advice on this medication for this indication in July 2008. This
stated that:
Tenofovir disoproxil (Viread®) is accepted for use within NHS
Scotland for the treatment of chronic hepatitis B in adults with
compensated liver disease, with evidence of active viral
replication, persistently elevated serum alanine aminotransferase
(ALT) levels and histological evidence of active inflammation
and/or fibrosis.
Access the advice of the Scottish Medicines Consortium:
http://www.scottishmedicines.org.uk/smc/5778.html
Published Date: 22 July 2009
